<DOC>
	<DOCNO>NCT00702468</DOCNO>
	<brief_summary>The purpose study evaluate maintenance effect long-term treatment Sativex® subject symptoms spasticity due Multiple Sclerosis ( MS ) receive long-term benefit treatment Sativex® .</brief_summary>
	<brief_title>Evaluate Maintenance Effect After Long-term Treatment With Sativex® Subjects With Symptoms Spasticity Due Multiple Sclerosis</brief_title>
	<detailed_description>This five week ( one week baseline four week randomise treatment period ) , multi-centre , placebo control , parallel group , randomize withdrawal study evaluate maintenance effect long-term treatment Sativex® subject symptoms spasticity due MS receive long-term benefit treatment Sativex® . Subjects select Supply Unlicensed Sativex® ( SUS ) name patient supply programme must receive Sativex® least 12 week prior study entry . Following informed consent screening , eligible subject enter study ( Visit 1 , Day 1 ) commence seven day open label baseline period , return randomisation visit ( Visit 2 , Day 7 ) , point randomise receive either Sativex® placebo ( randomised withdrawal period ) . Subjects return centre end study visit week five ( Visit 3 , Day 35 ) early withdraw treatment . Spasticity sleep disruption review dose diary complete day start baseline period completion withdrawal .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>Willing able give write informed consent participation study . Male female , age 18 year . Subject able ( investigator 's opinion ) willing comply study requirement . Diagnosed MS . Received Sativex relief spasticity least 12 week prior screen willing stop dosing supply duration study . Judged receive benefit show tolerability Sativex , investigator ' subject ' opinion . Takes minimum dose Sativex two spray per day . If receive diseasemodifying medication , must stable dose least three month prior screen , willing maintain duration study . Has stable regimen least 30 day prior study entry , medication nonpharmacological therapy may affect spasticity ; willing maintain duration study ( N.B . This three month prior study entry , case Interferon therapy ) . Willing allow general practitioner consultant , appropriate , notified participation study . Willing name notify responsible authority participation study Has concomitant disease disorder symptom spasticity may influence subject 's level spasticity . Unable rate level spasticity distinguish MS symptom . Currently receive prohibit medication ( Botulinum Toxin , Acomplia ( Rimonabant ) , unwilling stop comply duration study receive say medication/ therapy within three month prior screen visit . Unwilling stop Sativex treatment duration study . Any known suspected immediate family history schizophrenia , psychotic illness , severe personality disorder significant psychiatric disorder depression associate underlying condition . Has evidence cardiomyopathy . Has experience myocardial infarction clinically relevant cardiac dysfunction within last 12 month cardiac disorder , opinion investigator would put subject risk clinically relevant arrhythmia myocardial infarction . Has QT interval &gt; 450 m ( male ) &gt; 470 m ( female ) Visit 1 . Has secondary tertiary atrioventricular ( AV ) block sinus bradycardia ( HR &lt; 50bpm unless physiological ) sinus tachycardia ( HR &gt; 110bpm ) Visit 1 . Has diastolic blood pressure &lt; 50 mmHg &gt; 105 mmHg ( measure sit position rest five minute ) prior randomisation Has impair renal function e.g . creatinine clearance lower 50ml/min Visit 1 indicative renal impairment . Has significantly impair hepatic function , Visit 1 , investigator 's opinion . Female subject child bear potential male subject whose partner child bear potential , unless willing ensure partner use effective contraception study three month thereafter . Female subject pregnant , lactate plan pregnancy course study three month thereafter . Subjects receive IMP within 12 week Visit 1 . Any significant disease disorder , opinion investigator , may either put subject risk participation study , may influence result study , subject 's ability participate study . Following physical examination , subject abnormality , opinion investigator , would prevent safely participate study . Travel outside UK plan study . Unwilling abstain donation blood study . Subjects previously randomise study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Spasticity</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>